Showing posts with label populationbased. Show all posts
Showing posts with label populationbased. Show all posts

Thursday, September 19, 2013

0 Genome-Wide Association Studies of Asthma in Population-Based Cohorts Confirm Known and Suggested Loci and Identify an Additional Association near HLA


Open Access

RESEARCH ARTICLE


Genome-Wide Association Studies of Asthma in Population-Based Cohorts Confirm Known and Suggested Loci and Identify an Additional Association near HLA







Adaikalavan Ramasamy1,2,3#, Mikko Kuokkanen4#, Sailaja Vedantam5,6#, Zofia K. Gajdos5,6#, Alexessander Couto Alves2, Helen N. Lyon5,6, Manuel A. R. Ferreira7, David P. Strachan8, Jing Hua Zhao9, Michael J. Abramson10,Matthew A. Brown11, Lachlan Coin2, Shyamali C. Dharmage12, David L. Duffy7, Tari Haahtela13, Andrew C. Heath14, Christer Janson15, Mika Kähönen16, Kay-Tee Khaw17, Jaana Laitinen18, Peter Le Souef19, Terho Lehtimäki20, Australian Asthma Genetics Consortium collaborators¶, Pamela A. F. Madden14, Guy B. Marks21,Nicholas G. Martin7, Melanie C. Matheson12, Cameron D. Palmer5,6, Aarno Palotie22,23,24,25, Anneli Pouta26,27,Colin F. Robertson28, Jorma Viikari29, Elisabeth Widen23, Matthias Wjst30, Deborah L. Jarvis1,31, Grant W. Montgomery7, Philip J. Thompson32, Nick Wareham9, Johan Eriksson33,34,35,36, Pekka Jousilahti4, Tarja Laitinen37,38, Juha Pekkanen39,40, Olli T. Raitakari41,42, George T. O’Connor43,44, Veikko Salomaa4#*, Marjo-Riitta Jarvelin2,31,33,45,46#*, Joel N. Hirschhorn5,6,47#*

1 Respiratory Epidemiology and Public Health, Imperial College London, London, United Kingdom, 2 Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom, 3 Department of Medical and Molecular Genetics, King’s College London, London, United Kingdom, 4 Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland, 5 Divisions of Genetics and Endocrinology, Children’s Hospital, Boston, Massachusetts, United States of America, 6 Broad Institute, Cambridge, Massachusetts, United States of America, 7 The Queensland Institute of Medical Research, Brisbane, Australia, 8 Division of Community Health Sciences, St George’s, University of London, London, United Kingdom, 9 MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom, 10 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia,, 11 University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane, Australia, 12 Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, Australia, 13 Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, 14 Washington University School of Medicine, St. Louis, Missouri, United States of America, 15 Department of Medical Sciences: Respiratory Medicine and Allergology, Uppsala University, Uppsala, Sweden, 16Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland, 17 Clinical Gerontology Unit, Addenbrooke’s Hospital, Cambridge, United Kingdom, 18 Finnish Institute of Occupational Health, Oulu, Finland, 19 School of Paediatrics and Child Health, Princess Margaret Hospital for Children, Perth, Australia, 20 Department of Clinical Chemistry, University of Tampere and Tampere University Hospital, Tampere, Finland, 21 Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia, 22 Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom, 23 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland, 24 Medical and Population Genetics and Genetic Analysis Platform, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America, 25 Department of Medical Genetics, University of Helsinki and University Central Hospital, Helsinki, Finland, 26 Department of Children, Young People and Families, National Institute for Health and Welfare, Helsinki, Finland,27 Institute of Clinical Medicine/Obstetrics and Gynecology, University of Oulu, Oulu, Finland, 28 Respiratory Medicine, Murdoch Children’s Research Institute, Melbourne, Australia, 29 Department of Medicine, University of Turku, Turku, Finland,30 Helmholtz Zentrum Munchen German Research Center for Environmental Health, Munich-Neuherberg, Germany, 31 MRC Health Protection Agency (HPA) Centre for Environment and Health, Imperial College London, London, United Kingdom, 32Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, University of Western Australia, Perth, Australia, 33 National Institute for Health and Welfare, Helsinki, Finland, 34 Unit of General Practice, Helsinki University Central Hospital, Helsinki, Finland, 35 Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland, 36 Folkhälsan Research Center, Helsinki, Finland, 37 Department of Pulmonary Diseases and Clinical Allergology, Turku University Hospital, Turku, Finland, 38 University of Turku, Turku, Finland, 39 Department of Environmental Health, National Institute for Health and Welfare (THL), Kuopio, Finland, 40 Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland, 41 Research Centre of Applied and Preventive Medicine, University of Turku, Turku, Finland, 42 Department of Clinical Physiology, Turku University Hospital, Turku, Finland, 43Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America, 44 The National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, Massachusetts, United States of America, 45 Institute of Health Sciences, University of Oulu, Oulu, Finland, 46 Biocenter Oulu, University of Oulu, Oulu, Finland, 47 Department of Genetics, Harvard Medical School, Boston, Massachusetts, United States of America


Abstract Top


Rationale


Asthma has substantial morbidity and mortality and a strong genetic component, but identification of genetic risk factors is limited by availability of suitable studies.

Objectives


To test if population-based cohorts with self-reported physician-diagnosed asthma and genome-wide association (GWA) data could be used to validate known associations with asthma and identify novel associations.

Methods


The APCAT (Analysis in Population-based Cohorts of Asthma Traits) consortium consists of 1,716 individuals with asthma and 16,888 healthy controls from six European-descent population-based cohorts. We examined associations in APCAT of thirteen variants previously reported as genome-wide significant (P−85×10>


) and three variants reported as suggestive (P−75>). We also searched for novel associations in APCAT (Stage 1) and followed-up the most promising variants in 4,035 asthmatics and 11,251 healthy controls (Stage 2). Finally, we conducted the first genome-wide screen for interactions with smoking or hay fever.


Main Results


We observed association in the same direction for all thirteen previously reported variants and nominally replicated ten of them. One variant that was previously suggestive, rs11071559 in RORA, now reaches genome-wide significance when combined with our data (P = 2.4×10−9). We also identified two genome-wide significant associations: rs13408661 near IL1RL1/IL18R1 (PStage1+Stage2= 1.1×10−9), which is correlated with a variant recently shown to be associated with asthma (rs3771180), and rs9268516 in the HLA region (PStage1+Stage2 = 1.1×10−8), which appears to be independent of previously reported associations in this locus. Finally, we found no strong evidence for gene-environment interactions with smoking or hay fever status.

Conclusions


Population-based cohorts with simple asthma phenotypes represent a valuable and largely untapped resource for genetic studies of asthma.




Saturday, September 14, 2013

0 Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study

Thorax 68:658-663 doi:10.1136/thoraxjnl-2012-203109Epidemiology


  • Original article



Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study


Open Access









  1. Jeffrey A Johnson1


+Author Affiliations




  1. 1Department of Public Health Sciences, University of Alberta, Edmonton, Canada




  2. 2Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada




  3. 3Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada





  1. Correspondence toDr Jeffrey A Johnson, 2-040G Li Ka Shing Center for Health Research Innovation, 8602 112 Street, Department of Public Health Sciences, University of Alberta, Edmonton, Canada, AB T6G 2E1; jeff.johnson@ualberta.ca



  • Received 7 December 2012

  • Revised 7 February 2013

  • Accepted 2 March 2013

  • Published Online First 27 March 2013




Abstract



Background Guidelines recommend influenza vaccinations in all diabetic adults, but there is limited evidence to support vaccinating working-age adults (65>



Methods We identified all adults with diabetes, along with a sample of age-matched and sex-matched comparison subjects without diabetes, from 2000 to 2008, using administrative data from Manitoba, Canada. With multivariable Poisson regression, we estimated vaccine effectiveness (VE) on influenza-like illnesses (ILIs), pneumonia and influenza (PI) hospitalisations and all-cause (ALL) hospitalisations during periods of known circulating influenza. Analyses were replicated outside of influenza season to rule out residual confounding.



Results We included 543 367 person-years of follow-up, during which 223 920 ILI, 5422 PI and 94 988 ALL occurred. The majority (58%) of adults with diabetes were working age. In this group, influenza vaccination was associated with relative reductions in PI (43%, 95% CI 28% to 54%) and ALL (28%, 95% CI 24% to 32%) but not ILI (−1%, 95% CI −3% to 1%). VE was similar in elderly adults for ALL (33–34%) and PI (45–55%), although not ILI (12–13%). However, similar estimates of effectiveness were also observed for all three groups during non-influenza control periods.



Conclusions Working-age adults with diabetes experience similar benefits from vaccination as elderly adults, supporting current diabetes-specific recommendations. However, these benefits were also manifest outside of influenza season, suggesting residual bias. Vaccination recommendations in all high-risk adults would benefit from randomised trial evidence.

This Article







  1. Supplementary Data


  2. All Versions of this Article:

    1. thoraxjnl-2012-203109v1

    2. 68/7/658 most recent









This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ andhttp://creativecommons.org/licenses/by-nc/3.0/legalcode